Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

11P - The prognosis of rare histopathologic subtype of breast cancer


23 Nov 2019


Poster display session


Tumour Site

Breast Cancer


Soo Youn Bae


Annals of Oncology (2019) 30 (suppl_9): ix1-ix8. 10.1093/annonc/mdz416


S.Y. Bae1, J.Y. Kim2

Author affiliations

  • 1 Surgery, Korea University Anam Hospital, 136 705 - Seoul/KR
  • 2 Surgery, Jeju National University Hospital, 63241 - Jeju/KR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 11P


Breast cancer is a heterogeneous disease with various histopathologic subtypes. As the prevalence of special types of breast cancer other than invasive carcinoma of no special type (NST) is low, limited data about the clinical behavior and prognosis according to the histologic types were documented with discordant results. The purpose of this study was to analyze the characteristics and the prognosis of rare histopathologic subtype of breast cancer compared with NST and to understand better for proper management.


A total of 133,969 patients were analyzed in this study among the patients who were registered in the Korean Breast Cancer Society Registry database between January 1996 and March 2019 in Korea.


The prevalence of special types of breast cancer other than NST was 13.7% (n = 18,633). The patients with lobular, mucinous, tubular, papillary, and cribriform carcinoma presented as luminal A subtype much more than NST (77.6%, 74.6%, 77.2%, 57.4%, and 78.1% vs 47.5%, respectively, p < 0.001). A micropapillary carcinoma included more luminal B subtype with even high K-67 expression or positive HER2 than NST (40.9% vs 29.5%, p < 0.001). Typically, medullary and metaplastic carcinoma included more triple negative breast cancer (44.8% and 64.8% vs 13.5%, p < 0.001) than NST. In survival analysis, lobular (HR 0.879, p = 0.029), mucinous (HR 0.529, p < 0.001), tubular (HR 0.781, p < 0.001), papillary (HR 0.728, p < 0.001), medullary (HR 0.500, p < 0.001), and cribriform carcinoma (HR 0.291, p = 0.001) showed better overall survival than NST, and metaplastic carcinoma (HR 1.995, p < 0.001) showed worse outcome significantly. However, after adjusting for age, stage, molecular subtypes, grade, and lymphovascular invasion, only metaplastic carcinoma showed different overall (HR 1.762, p < 0.001) and breast cancer-specific survival (HR 1.685, p = 0.012) from NST.


In conclusion, invasive breast cancer had specific clinical and pathologic features according to the histopathologic subtype. However, special types of breast cancer other than NST have similar survival outcomes compared to NST when adjusting for other prognostic factors, except for metaplastic carcinoma.

Clinical trial identification

Editorial acknowledgement

This research was supported by the Korean Breast Cancer Society.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.